Ivy Wong is a partner in Baker McKenzie's Hong Kong office. She is the chair of the Firm's Capital Markets Practice Group in Asia Pacific and serves on the Global Capital Markets Steering Committee. Ivy is a Hong Kong, English and New York qualified partner based in Hong Kong.
Ivy was shortlisted for Euromoney Asia Women in Business Law Awards from 2019 to 2021, and is named one of the leading Capital Markets practitioners in Hong Kong. She has been quoted and interviewed by international media and journals including Bloomberg, The Wall Street Journal, The Economist and Reuters.
She also serves as the Hong Kong lead partner of Baker McKenzie's BakerWomen Committee and is a member of the Firm's Junior Lawyer Committee.
Ivy's practice focuses on IPOs, securities offerings, corporate finance, mergers and acquisitions, compliance and general corporate work. She has led many unprecedented and high-profile securities offerings and cross-border transactions, including many successful listings that are first of its kind on the Hong Kong Stock Exchange and multiple landmark and innovative deals that won industry awards.
Ivy has extensive expertise in handling international clients and resolving issues arising from different regulatory regimes. Her clients include many reputable listed companies, multinational corporates and conglomerates, financial institutions and fund houses.
Representative Legal Matters
Initial public offerings
- Advised CLSA Limited and other underwriters on Joincare Pharmaceutical Group Industry Co., Ltd.'s GDR listing on the SIX Swiss Exchange. Joincare Pharmaceutical is an innovation-driven integrated pharmaceutical company that combines pharmaceutical R&D, manufacturing and commercialization. It is a pioneer and leader in the field of complex formulation in China. The company has been listed on the Shanghai Stock Exchange since June 2001.
- Advised Sony Music Entertainment as a cornerstone investor on the IPO and listing of shares of Cloud Village Inc. on the main board of the Hong Kong Stock Exchange. The deal value was HKD 3.28 billion.
- Advised SF Real Estate Investment Trust on its REIT IPO and listing on the main board of the Hong Kong Stock Exchange, which is the first logistics-focused REIT in Hong Kong.
- Advised 3SBio Inc. on the spin-off listing of its subsidiary, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., on the STAR Market, the new Science and Technology Innovation Board of the Shanghai Stock Exchange launched in July 2019.
Equity and debt fund raisings by listed issuers
- Advised SK Holdings Co., Ltd., a Korea listed company, on the successful private placement of shares in ESR Cayman Limited for HKD 3.15 billion.
- Advised 3SBio Inc. on the issuance of its new EUR 320 million zero-coupon convertible bonds due 2025 through its SPV, and on the concurrent repurchase of its existing convertible bonds. This deal is one of the very few concurrent issue and repurchase of convertible bonds in the market.
- Advised the controlling shareholder of a HK listed company on the transfer of margin loan facility to a major fund investor involving the investor's concurrent investment in the company during the blackout period in response to the unprecedented market volatility at its peak during the COVID-19 pandemic. The transaction was extremely complex, time sensitive and unconventional, which was intensified by different regulatory complexities and technicalities that needed to be overcome in order to achieve a successful completion.
- Advised BOCOM International Holdings, a HK listed company, on a financing transaction that facilities a mandatory general offer made by a controlling shareholder of a listed company. The deal was successfully completed in the midst of a challenging market during the COVID-19 pandemic.
Mergers and Acquisitions
- Advised BOCOM International Holdings, a HK listed company, on an investment transaction involving its subscription of preference shares in a new tech company in the pharmaceutical, biotech and biomed sector. The deal was successfully completed in the midst of a challenging market during the COVID-19 pandemic.
- Advised Tencent on its pre-IPO investment in Koolearn Technology Holding Limited and its rights as a substantial shareholder of Koolearn.
- Notable Practitioner (Capital Markets: Equity, Hong Kong) – IFLR1000 (2022)
- Shortlisted for Euromoney Asia Women in Business Law Awards from 2019 to 2021; named one of the leading Capital Markets practitioners in Hong Kong
- New York~North America (2009)
- England & Wales (2003)
- Hong Kong (2002)
- The London School of Economics and Political Science (LL.M.)
- University of Hong Kong (LL.B. and P.C.LL.)
- University of British Columbia (Bachelor of Commerce)
Contributor, "Hong Kong Sponsor Due Diligence Guidelines", 2020
Contributor, "Coronavirus Considerations for Capital Markets," Baker McKenzie, 2020
Contributor, "Coronavirus Under the Capital Markets Microscope," Baker McKenzie, 2020
Commentator, "The Future of Capital Raising in Biotech and Pharma," Baker McKenzie, 2020
Firm Committee Memberships
- Asia Pacific Capital Markets Steering Committee – Chair
- Global Capital Markets Steering Committee – AP Representative
- BakerWomen – Hong Kong Champion
- Junior Lawyer Committee – Member